Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines Inc - Ordinary Shares

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Revolution Medicines, with a price target of $144.00. Accor...

LifeSci Capital Sticks to Its Buy Rating for Revolution Medicines (RVMD)

In a report released today, Michael Schmidt from Guggenheim maintained a Buy rating on Revolution Medicines, with a price target of $160.00. Schmid...

Revolution Medicines (RVMD) Receives a Buy from Guggenheim

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medpace Holdings (MEDP – Research Report), Revolutio...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RVMD	$96.75	0.00%	1.20M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RVMD	$96.75	0%	1.20M
3
4
5
6

RVMD

RVMD

Get Revolution Medicines Inc - Ordinary Shares Data in Excel

Get Revolution Medicines Inc - Ordinary Shares Data in Excel